Cytokinetics, Inc. (CYTK) Tops Q3 EPS by 5c; Guides FY11 Revs Below
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $62.33 -0.84%
Revenue Growth %: +2,004.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
ORPB, PBCO, SICP, More
Revenue Growth %: +2,004.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q3 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.36 million.
Sees FY2011 revenue of $3.0-$4.0 million, versus the consensus of $5.62 million.
Sees FY2011 revenue of $3.0-$4.0 million, versus the consensus of $5.62 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Consumer Portfolio Services (CPSS) Reports Q3 EPS of $0.30
- FVCBankcorp, Inc. (FVCB) Misses Q3 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
